Exagen Inc

NASDAQ XGN

Data sourced from

and

Download Data

Exagen Inc Cash Flow Coverage Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -11.64%

Exagen Inc Cash Flow Coverage Ratio 1 year YoY Change (%) is -11.64% for the Trailing 12 Months (TTM) ending March 31, 2024, a 67.80% change year over year. The cash flow coverage ratio evaluates a company's ability to cover its interest expense with its operating cash flow after deducting capital expenditures. It is calculated by dividing the difference between operating cash flow and capital expenditures by interest expense. This ratio indicates the company's ability to generate enough cash flow to service its interest payments. A higher ratio signifies better coverage and financial stability. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Exagen Inc Cash Flow Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -14.89, a -36.13% change year over year.
Exagen Inc Cash Flow Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -10.94, a -80.19% change year over year.
Exagen Inc Cash Flow Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was -6.07, a -64.93% change year over year.
Exagen Inc Cash Flow Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was -3.68, a -37.22% change year over year.

NASDAQ: XGN

Exagen Inc

CEO	Mr. Kamal Adawi M.S., MBA
IPO Date	Sept. 19, 2019
Location	United States
Headquarters	1261 Liberty Way, Vista, CA, United States, 92081
Employees	174
Sector	Healthcare
Industry	Diagnostics & research

Description

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Key trends